A real-life observational study was conducted to evaluate the effectiveness and safety of tralokinumab, a monoclonal antibody, in adolescents with severe atopic dermatitis (AD). The study included 14 adolescents who had failed previous treatments and were treated with tralokinumab for 12 to 16 weeks. The primary outcome was improvement in clinical scores, specifically the Eczema Area and Severity Index (EASI) and the Peak Pruritus Numerical Rating Scale (PP-NRS). The study found that tralokinumab was effective in improving EASI and PP-NRS scores in most patients, with 28.6% achieving an EASI 75 and 42.8% experiencing a four-point or higher reduction in PP-NRS. The most common adverse events were flare of AD and injection-site reactions. The study concluded that tralokinumab is effective and well-tolerated in adolescents with severe AD, but longer-term studies are needed. [Extracted from the article]